Avantium Technologies Announces Collaboration with GlaxoSmithKline
News Apr 21, 2006
Avantium Technologies have announced that they have a collaboration with GlaxoSmithKline for the extensive screening of several GSK pharmaceutical compounds utilizing Avantium’s high-throughput polymorph, salt and co-crystal screening capabilities to find novel solid forms.
Avantium Technologies is an innovation-based company and its unique integrated screening platform provides a fast and efficient way to explore a wide array of crystallization conditions to generate and identify novel solid forms.
“We welcome this great opportunity to collaborate with GlaxoSmithKline,” said Guus Scheefhals, Chief Business Officer of Avantium Technologies. “It is an honor to contribute to the development of GSK’s therapeutic products by using our highthroughput technology platform and rational experimental design strategy. This intensive partnership is a valuable recognition of our capabilities.“
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE